GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (NAS:DCTH) » Definitions » 3-Year ROIIC %

DCTH (Delcath Systems) 3-Year ROIIC % : -434.13% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Delcath Systems 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Delcath Systems's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -434.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Delcath Systems's 3-Year ROIIC % or its related term are showing as below:

DCTH's 3-Year ROIIC % is ranked worse than
94.88% of 820 companies
in the Medical Devices & Instruments industry
Industry Median: -2.035 vs DCTH: -434.13

Delcath Systems 3-Year ROIIC % Historical Data

The historical data trend for Delcath Systems's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems 3-Year ROIIC % Chart

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.86 -54.46 -191.55 1,031.43 -434.13

Delcath Systems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -434.13 - - -

Competitive Comparison of Delcath Systems's 3-Year ROIIC %

For the Medical Devices subindustry, Delcath Systems's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delcath Systems's 3-Year ROIIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Delcath Systems's 3-Year ROIIC % falls into.



Delcath Systems 3-Year ROIIC % Calculation

Delcath Systems's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -38.182 (Dec. 2023) - -21.303 (Dec. 2020) )/( 13.501 (Dec. 2023) - 9.613 (Dec. 2020) )
=-16.879/3.888
=-434.13%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Delcath Systems  (NAS:DCTH) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Delcath Systems 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Delcath Systems's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems Business Description

Traded in Other Exchanges
Address
566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Executives
Gil Aharon director 15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Salamon Steven A J director 25 ADMIRAL ROAD, TORONTO A6 M5R 2L4
Vojo Vukovic officer: See Remarks C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Gerard J Michel director, officer: Chief Executive Officer 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Sandra Pennell officer: See Remarks C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
David L. Hoffman officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
John Purpura officer: EVP, Regulatory Affairs 600 FIFTH AVENUE, 23RD FLOOR, NEW YORK NY 10020
John Richard Sylvester director C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Rosalind Advisors, Inc. director, other: See Remarks 15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Kevin Muir officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Anthony Dias officer: Vice President of Finance C/O SEACHANGE INTERNATIONAL, 50 NAGOG PARK, ACTON MA 01720
Johnny John officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Christine Padula officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Simon Pedder director 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203